Transforming Care for AMD

Dr. Murtaza Adam, vitreoretinal specialist at Colorado Retina Associates and EyePoint Pharmaceuticals, invites local eye care providers to an educational dinner on Thursday, March 13, 2025 at 6:00 PM at Sushi Den restuaurant in the Platt Park neighborhood of Denver. This event offers a unique opportunity for optometrists and ophthalmologists to learn more about innovative, novel treatment options for wet age-related macular degeneration (wet AMD).

Dr. Adam will discuss Eyepoint's Phase 3 clinical trial, LUCIA, which is actively enrolling participants. The trial focuses on Duravyu, a novel sustained-release therapy designed to reduce the injection treatment burden by delivering vorolanib, a selective tyrosine kinase inhibitor. Dr. Adam will also explore how this potentially more durable therapy for wet AMD can help reduce rates of under-treatment and irreversible vision loss in patients, potentially changing the landscape for this common condition.

This event is open to licensed, practicing eye care providers- optometrists and ophtalmologists only. Limited capacity, RSVP required. Please note, NO CE credit will be issued for attendance, this is an educational opportunity only. Coursed dinner included with admission.

Host or Publisher Kendall Johnson